Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe ...

Pericarditis recurrence in lupus is more likely — and has a dose-dependent relationship — with oral prednisone treatment, ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

A common form of lupus is systemic lupus erythematosus. Systemic lupus erythematosus affects the whole body and can attack virtually any part of it, including skin, major organs, hair, muscles ...

Merck tested its oral TLR7/8 inhibitor enpatoran in two forms of lupus. The company reported positive phase 2 data from the cohort of cutaneous lupus erythematosus (CLE) patients late last year.

A new study sought to identify the frequency and determinants of flares for with people with systemic lupus erythematosus (SLE) with persistently active disease (PAD). Researchers found that both ...

CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med 2021;385:567-569. [2] Mackensen A. et al., Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus; ...

Oral sex was considered a taboo subject up until the sexual revolution of the 1960s, thanks in part to a conservative lens caused by fear of World War II and the importance of reproduction as a ...

The latest study builds on earlier research about systemic lupus erythematosus, including findings that the first symptoms of more than half of lupus patients were initially misdiagnosed as ...

At the 32nd week of gestation, her oral glucose tolerance test (OGTT ... with typical cutaneous lesions resembling those seen in subacute cutaneous lupus erythematosus (SCLE) (3). A retrospective ...

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, P. R. China ...

Research projects that will improve outcomes for patients with systemic lupus erythematosus, develop long-acting therapies to treat hypertension and organ injury, and create pathways to vision for ...